SSG
JAZZ icon

Summit Securities Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Summit Securities Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-200
Closed -$35K – 534
2015
Q1 		$35K Buy
+200
New +$34.3K 0.03% 227
2013
Q3 		– Sell
-970
Closed -$67K – 484
2013
Q2 		$67K Buy
+970
New +$59.3K 0.03% 163

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Summit Securities Group's JAZZ Position: Q2 2015 in Review

Summit Securities Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2015, closing a stake of 200 shares — an estimated $35K sold.

Summit Securities Group first reported a position in JAZZ in Q2 2013 and held it in 2 quarters. The position peaked at $67K in Q2 2013. 373 funds tracked by Wall St. Rank hold JAZZ as of Q2 2015.

  • Summit Securities Group reported no remaining Jazz Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Summit Securities Group sold 200 Jazz Pharmaceuticals shares in Q2 2015, an estimated $35K.
  • Summit Securities Group first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Summit Securities Group's Jazz Pharmaceuticals position peaked at $67K in Q2 2013.
  • 373 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2015.

Based on Summit Securities Group's 13F filing for Q2 2015, filed 5 Aug 2015.